These findings have several implications: first, evobrutinib, a covalent BTK inhibitor currently trialed for treatment of relapsing MS, is capable of entering the CNS in relevant concentrations, efficiently binding available BTK molecules. Here, BTK is linked to myeloid sarcoma.